Erasca to Present at the Morgan Stanley 23rd Annual Global Healthcare Conference

Erasca (Nasdaq: ERAS), a clinical-stage precision oncology company focused on RAS/MAPK pathway-driven cancer therapies, will participate in the Morgan Stanley 23rd Annual Global Healthcare Conference.

Rhea-AI Summary

Erasca (Nasdaq: ERAS), a clinical-stage precision oncology company focused on RAS/MAPK pathway-driven cancer therapies, will participate in the Morgan Stanley 23rd Annual Global Healthcare Conference. The company's management will deliver a presentation on Tuesday, September 9, 2025, at 3:20 PM ET at the Sheraton New York Times Square and engage in one-on-one investor meetings.

Investors can access a live audio webcast of the presentation through Erasca.com/events, with a replay available for 30 days following the event.

Argus Sep 2 session

+1.91% close to close Open Argus

Details

News Market Reaction – ERAS

On Sep 2, the day this news came out, ERAS closed 1.91% above the previous close.

Data tracked by StockTitan Argus for the Sep 2 session.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

SAN DIEGO, Sept. 02, 2025 (GLOBE NEWSWIRE) -- Erasca, Inc. (Nasdaq: ERAS), a clinical-stage precision oncology company singularly focused on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers, today announced its participation in the Morgan Stanley 23rd Annual Global Healthcare Conference being held at the Sheraton New York Times Square in New York, NY. Management will present on Tuesday, September 9, 2025, at 3:20 pm Eastern Time and will also participate in one-on-one investor meetings.

A live audio webcast of the event will be available online at Erasca.com/events. An archived replay of the event will be available for 30 days following the webcast at Erasca.com/events.

About Erasca
At Erasca, our name is our mission: To erase cancer. We are a clinical-stage precision oncology company singularly focused on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers. Our company was co-founded by leading pioneers in precision oncology and RAS targeting to create novel therapies and combination regimens designed to comprehensively shut down the RAS/MAPK pathway for the treatment of patients with cancer. We believe our team’s capabilities and experience, further guided by our scientific advisory board which includes the world’s leading experts in the RAS/MAPK pathway, uniquely position us to achieve our bold mission of erasing cancer.

Contact:
Joyce Allaire
LifeSci Advisors, LLC
jallaire@lifesciadvisors.com

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

When is Erasca (ERAS) presenting at the Morgan Stanley Healthcare Conference 2025?

Erasca will present on Tuesday, September 9, 2025, at 3:20 PM Eastern Time at the Sheraton New York Times Square.

How can investors access Erasca's Morgan Stanley conference presentation?

Investors can access the live audio webcast at Erasca.com/events, with a replay available for 30 days after the event.

What type of company is Erasca (ERAS)?

Erasca is a clinical-stage precision oncology company focused on developing therapies for patients with RAS/MAPK pathway-driven cancers.

Where will the Morgan Stanley Healthcare Conference 2025 be held?

The conference will be held at the Sheraton New York Times Square in New York, NY.